Quantum BioPharma (QNTM, Financial) has kicked off a collaborative study with Massachusetts General Hospital (MGH) to explore a new imaging method to assess myelin health in multiple sclerosis (MS) patients. This initiative marks a significant step as the first participant has undergone scanning using a novel positron emission tomography (PET) technique.
The focal point of this research is the PET tracer 18F3F4AP, crafted by Dr. Pedro Brugarolas from MGH’s Radiology department and a Harvard Medical School Assistant Professor. Previous investigations in both animal and human models have demonstrated that 18F3F4AP is particularly effective in detecting demyelinated lesions, thanks to its advantageous pharmacokinetics. This makes it a promising candidate for tracking the efficacy of treatments aimed at promoting remyelination or providing neuroprotection in MS.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Quantum BioPharma Ltd (QNTM, Financial) is $169.00 with a high estimate of $169.00 and a low estimate of $169.00. The average target implies an upside of 687.88% from the current price of $21.45. More detailed estimate data can be found on the Quantum BioPharma Ltd (QNTM) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Quantum BioPharma Ltd's (QNTM, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
